Retinoic acid and arsenic trioxide trigger degradation of mutated npm1, resulting in apoptosis of aml cells.

The present invention relates to methods and pharmaceutical compositions for the treatment of acute myeloid leukemia. In particular, the present invention relates to a method for treating NPM-1-driven acute myeloid leukemia (AML) in a subject in need thereof comprising administering the subject with a therapeutically effective amount of at least one arsenic compound and with a therapeutically effective amount of at least one retinoid.

Keywords: AML - Combination - Arsenate
Patent Application number: EP13306891.6
Inventors:
Maria Paola MARTELLIBrunangelo FALINIAli BAZARBACHIHugues BLAUDIN DE THEHiba EL HAJJ
Publications:
Blood. 2015 May 28;125(22):3447-54. doi: 10.1182/blood-2014-11-612416. Epub 2015 Mar 23.

Reference:

BIO13408-T1

Business Developper
contact
Anne COCHI
Anne COCHI
Business Development Manager
Patent filling date: 2013-12-30
Second indication: Yes

You might also be interested in